Department of Dermatology, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Department of Dermatology and Venereology, All India Institute of Medical Sciences, Patna, India.
Dermatol Ther. 2020 Nov;33(6):e14140. doi: 10.1111/dth.14140. Epub 2020 Sep 3.
Coronavirus 2019 (COVID 19) was first detected in December 2019 in China. It has become a pandemic. With concern about therapies that may decrease immunity and enhance the severity of an individual's COVID-19 infection, leading to a possibly fatal outcome, use of immunosuppressants has become an important concern. This work focuses on management of various skin diseases individuals lacking immunity to COVID-19 but requiring a systemic immunosuppressant, keeping in view the challenge of the COVID 19 pandemic and that our knowledge of this virus and its effects on the immune system are incomplete including knowledge as to an individual's immunity after COVID-19 infection.
2019 年冠状病毒（COVID-19）于 2019 年 12 月在中国首次发现。它已成为一种大流行病。由于担心可能会降低免疫力并加重个体 COVID-19 感染严重程度的治疗方法，导致可能致命的后果，因此免疫抑制剂的使用已成为一个重要关注点。这项工作重点关注管理各种皮肤疾病患者，这些患者对 COVID-19 缺乏免疫力，但需要全身性免疫抑制剂，鉴于 COVID-19 大流行的挑战以及我们对该病毒及其对免疫系统的影响的了解尚不完全，包括在 COVID-19 感染后个体免疫力的知识。
